Stoneridge Investment Partners LLC Invests $515,000 in PAREXEL International Co. (PRXL)

Stoneridge Investment Partners LLC Invests $515,000 in PAREXEL International Co. (PRXL)

Stoneridge Investment Partners LLC bought a new stake in shares of PAREXEL International Co. (NASDAQ:PRXL) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 8,158 shares of the medical research company’s stock, valued at approximately $515,000.

Several other large investors have also recently modified their holdings of the stock. Glen Harbor Capital Management LLC increased its stake in shares of PAREXEL International by 7.1% in the first quarter. Glen Harbor Capital Management LLC now owns 2,520 shares of the medical research company’s stock valued at $159,000 after buying an additional 168 shares in the last quarter. Acrospire Investment Management LLC increased its stake in shares of PAREXEL International by 187.5% in the third quarter. Acrospire Investment Management LLC now owns 2,300 shares of the medical research company’s stock valued at $160,000 after buying an additional 1,500 shares in the last quarter. Elkfork Partners LLC purchased a new stake in shares of PAREXEL International during the fourth quarter valued at approximately $188,000. Sapphire Star Partners LP purchased a new stake in shares of PAREXEL International during the fourth quarter valued at approximately $230,000. Finally, Capstone Asset Management Co. increased its stake in shares of PAREXEL International by 3.8% in the first quarter. Capstone Asset Management Co. now owns 4,409 shares of the medical research company’s stock valued at $278,000 after buying an additional 160 shares in the last quarter. Institutional investors own 91.44% of the company’s stock.

Shares of PAREXEL International Co. (NASDAQ:PRXL) traded up 1.89% on Friday, reaching $68.86. 751,401 shares of the company traded hands. The firm’s 50 day moving average is $62.83 and its 200 day moving average is $63.85. The company has a market capitalization of $3.51 billion, a P/E ratio of 24.44 and a beta of 0.82. PAREXEL International Co. has a one year low of $51.16 and a one year high of $72.32.

PAREXEL International (NASDAQ:PRXL) last announced its quarterly earnings results on Wednesday, May 3rd. The medical research company reported $0.74 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. PAREXEL International had a return on equity of 29.92% and a net margin of 6.34%. The firm had revenue of $529.30 million for the quarter, compared to analyst estimates of $529.38 million. During the same period last year, the firm posted $0.89 earnings per share. The business’s revenue for the quarter was up .4% on a year-over-year basis. Analysts expect that PAREXEL International Co. will post $3.24 earnings per share for the current fiscal year.

PRXL has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of PAREXEL International from a “hold” rating to a “buy” rating and set a $78.00 target price on the stock in a research note on Thursday, January 26th. Jefferies Group LLC boosted their target price on shares of PAREXEL International from $64.00 to $67.00 and gave the company a “hold” rating in a research note on Tuesday, January 24th. Citigroup Inc downgraded shares of PAREXEL International from a “buy” rating to a “neutral” rating in a research note on Friday, February 3rd. Credit Suisse Group AG downgraded shares of PAREXEL International from an “outperform” rating to a “neutral” rating in a research note on Monday, February 6th. Finally, Mizuho initiated coverage on shares of PAREXEL International in a research note on Thursday, March 23rd. They issued a “neutral” rating and a $86.00 target price on the stock. Four equities research analysts have rated the stock with a sell rating and eleven have given a hold rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $68.95.

In other news, SVP Sybrand Pretorius sold 8,050 shares of PAREXEL International stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $65.12, for a total transaction of $524,216.00. Following the sale, the senior vice president now directly owns 9,950 shares of the company’s stock, valued at $647,944. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gadi Saarony sold 2,325 shares of PAREXEL International stock in a transaction dated Thursday, February 9th. The shares were sold at an average price of $64.54, for a total value of $150,055.50. Following the sale, the insider now directly owns 14,208 shares in the company, valued at $916,984.32. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.

PAREXEL International Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Co. (NASDAQ:PRXL).

Related posts

Leave a Comment